Ashwin N Ananthakrishnan1, Hamed Khalili, Mingyang Song, Leslie M Higuchi, Paul Lochhead, James M Richter, Andrew T Chan. 1. *Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts; †Division of Gastroenterology and Nutrition, Children's Hospital Boston and Harvard Medical School, Boston, Massachusetts; ‡Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, Boston, Massachusetts; §Departments of Nutrition and Epidemiology, Harvard School of Public Health, Boston, Massachusetts; and ‖Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
Abstract
INTRODUCTION: High intake of dietary n-3 polyunsaturated fatty acids (PUFA) is associated with a decreased risk of ulcerative colitis (UC) and Crohn's disease (CD). However, results have been heterogeneous suggesting that genetic variations in PUFA metabolism may modify this risk. METHODS: We conducted a case-control study nested within 2 prospective cohorts, the Nurses' Health Study (NHS) and NHS II. Among women providing blood (n = 62,437) or buccal cells (n = 59,543) for genotyping, we confirmed new diagnoses of CD or UC. Dietary intake was assessed 4 years before diagnosis. Confirmed cases were matched 1:2 to controls. Subjects were genotyped for single nucleotide polymorphisms at CYP4F3, FADS1, and FADS2 loci. Conditional logistic regression models examined the interaction between genotype, n3:n6 PUFA intake and risk of CD and UC. RESULTS: Our study included 101 CD and 139 UC patients matched to 495 controls. On multivariable analysis, high intake of n3:n6 PUFA (above median) demonstrated a trend toward reduced risk of UC (Odds ratio [OR] 0.71, 95% confidence interval [CI], 0.47-1.09, P = 0.11). High n3:n6 PUFA intake was associated with a reduced risk of UC in individuals with the GG/AG genotype at a single nucleotide polymorphism in CYP4F3 (OR 0.57, 95% CI, 0.32-0.99) but not those with the AA genotype (OR 0.95, 95% CI, 0.47-1.93) (P-interaction = 0.049). No gene-diet interactions were noted for CD. CONCLUSIONS: The association between dietary n3:n6 PUFA intake and risk of UC may be modified variants at CYP4F3. Further gene-environment studies of the association between diet and IBD risk are warranted.
INTRODUCTION: High intake of dietary n-3 polyunsaturated fatty acids (PUFA) is associated with a decreased risk of ulcerative colitis (UC) and Crohn's disease (CD). However, results have been heterogeneous suggesting that genetic variations in PUFA metabolism may modify this risk. METHODS: We conducted a case-control study nested within 2 prospective cohorts, the Nurses' Health Study (NHS) and NHS II. Among women providing blood (n = 62,437) or buccal cells (n = 59,543) for genotyping, we confirmed new diagnoses of CD or UC. Dietary intake was assessed 4 years before diagnosis. Confirmed cases were matched 1:2 to controls. Subjects were genotyped for single nucleotide polymorphisms at CYP4F3, FADS1, and FADS2 loci. Conditional logistic regression models examined the interaction between genotype, n3:n6 PUFA intake and risk of CD and UC. RESULTS: Our study included 101 CD and 139 UC patients matched to 495 controls. On multivariable analysis, high intake of n3:n6 PUFA (above median) demonstrated a trend toward reduced risk of UC (Odds ratio [OR] 0.71, 95% confidence interval [CI], 0.47-1.09, P = 0.11). High n3:n6 PUFA intake was associated with a reduced risk of UC in individuals with the GG/AG genotype at a single nucleotide polymorphism in CYP4F3 (OR 0.57, 95% CI, 0.32-0.99) but not those with the AA genotype (OR 0.95, 95% CI, 0.47-1.93) (P-interaction = 0.049). No gene-diet interactions were noted for CD. CONCLUSIONS: The association between dietary n3:n6 PUFA intake and risk of UC may be modified variants at CYP4F3. Further gene-environment studies of the association between diet and IBD risk are warranted.
Authors: Stacey A Missmer; Jorge E Chavarro; Susan Malspeis; Elizabeth R Bertone-Johnson; Mark D Hornstein; Donna Spiegelman; Robert L Barbieri; Walter C Willett; Susan E Hankinson Journal: Hum Reprod Date: 2010-03-23 Impact factor: 6.918
Authors: Hamed Khalili; Ashwin N Ananthakrishnan; Gauree G Konijeti; Leslie M Higuchi; Charles S Fuchs; James M Richter; Andrew T Chan Journal: Inflamm Bowel Dis Date: 2015-02 Impact factor: 5.325
Authors: Punyanganie S A de Silva; Anja Olsen; Jane Christensen; Erik Berg Schmidt; Kim Overvaad; Anne Tjonneland; Andrew R Hart Journal: Gastroenterology Date: 2010-10-13 Impact factor: 22.682
Authors: Bénédicte Fontaine-Bisson; Thomas M S Wolever; Jean-Louis Chiasson; Rémi Rabasa-Lhoret; Pierre Maheux; Robert G Josse; Lawrence A Leiter; N Wilson Rodger; Edmond A Ryan; Philip W Connelly; Paul N Corey; Ahmed El-Sohemy Journal: Am J Clin Nutr Date: 2007-09 Impact factor: 7.045
Authors: A Tjonneland; K Overvad; M M Bergmann; G Nagel; J Linseisen; G Hallmans; R Palmqvist; H Sjodin; G Hagglund; G Berglund; S Lindgren; O Grip; D Palli; N E Day; K-T Khaw; S Bingham; E Riboli; H Kennedy; A Hart Journal: Gut Date: 2009-07-23 Impact factor: 23.059
Authors: Hamed Khalili; Simon S M Chan; Paul Lochhead; Ashwin N Ananthakrishnan; Andrew R Hart; Andrew T Chan Journal: Nat Rev Gastroenterol Hepatol Date: 2018-09 Impact factor: 46.802
Authors: Willy Albert Flegel; Kshitij Srivastava; Tristan Michael Sissung; Barry Ronald Goldspiel; William Douglas Figg Journal: Vox Sang Date: 2020-09-30 Impact factor: 2.996
Authors: Elizabeth A Scoville; Margaret M Allaman; Dawn W Adams; Amy K Motley; Shannon C Peyton; Sarah L Ferguson; Sara N Horst; Christopher S Williams; Dawn B Beaulieu; David A Schwartz; Keith T Wilson; Lori A Coburn Journal: Sci Rep Date: 2019-02-27 Impact factor: 4.379